International Vaccine Institute

Among its notable achievements is the creation of an oral cholera vaccine, which the institute licenses to manufacturing partners worldwide. In the context of the Biovac project in Cape Town, South Africa, IVI is transferring this technology to enable local production of the vaccine as the first product at the new multi-vaccine manufacturing facility. This supports broader goals of strengthening vaccine manufacturing capabilities in Africa.

Headquartered in Seoul, South Korea, IVI collaborates with a network of global partners including governments, international health organizations such as the World Health Organization and Gavi, the Vaccine Alliance, as well as academic and research institutions. Its funding comes from a diverse group of donor countries and philanthropic organizations, ensuring its independence and focus on public health rather than profit.

Within the vaccine industry, IVI serves as a bridge between basic scientific research and practical application, emphasizing equitable distribution and capacity building in regions with limited resources. It does not engage in commercial manufacturing itself but facilitates technology transfer to local producers, positioning it as a vital contributor to global vaccine security and pandemic preparedness.